Translational Research. New Findings and Potential Future Applications in Pancreatic Adenocarcinoma
The current achievements in pancreatic cancer diagnosis and treatment are disappointing for patients and clinicians alike. Still, in the dawn of 2012, most patients are diagnosed at a late stage where cure is not feasible, with the majority going to succumb within the same year of diagnosis. Thus, the only hope for early and diagnosis and radical treatment is the invention of diagnostic and prognostic tests which might predict accurately patients who may develop this disease and those who have the most aggressive potential, so clinician adopt the appropriate strategy. In this paper we summarize the findings from the three most interesting research abstract as presented at the 2012 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In particular, we focus on Abstract #160 which shows the diagnostic utility of microRNA serum profiling in pancreatic cancer patients, on Abstract #201 which suggests a potential prognostic role of transforming growth factor (TGF)-beta pathway in advanced pancreatic cancer, and on Abstract #165 which shows that protein S100A4 might be a new, potentially useful, predictive biomarker of gemcitabine efficacy.
Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010 Dec,4(4), 433-449.
Schultz NA, Dehlendorff C, Werner J, et al. Diagnostic microRNA serum profile in pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2012 Jan 30,30(4_suppl), 160.
Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004 Mar 2,101(9), 2999-3004.
Javle MM, Tan D, Li Y, et al. Transforming growth factor (TGF) beta pathway and clinical outcome of pancreatic cancer. J Clin Oncol (Meeting Abstracts) 2012 Jan 30,30(4_suppl), 201.
Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2006 Feb,17(1-2), 29-40.
Tempero MA, Moughan J, Kim GE, et al. S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704. J Clin Oncol (Meeting Abstracts) 2012 Jan 30,30(4_suppl), 165.
Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007 Jul 15,67(14), 6786-6795.
Copyright (c) 2014 Alexios S Strimpakos, Kostas N Syrigos, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.